Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisaftoclax (APG-2575) in R/R CLL/SLL
NCT04215809Phase 1Recruiting
- Sponsor
- Ascentage Pharma
- Start
- Mar 2020
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of lisaftoclax in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (3 arms), sponsored by Ascentage Pharma. Primary endpoints: Dose Limiting Toxicity at 42 days and Maximum Tolerated Dose at 42 days. Started Mar 2020; status: recruiting.
02
Drugs
lisaftoclax
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT04215809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04215809.